Samsung Biologics Co.,Ltd. (207940.KS)
KRW 1072000.0
(2.19%)
KRW 1072000.0
(2.19%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2641.36 Billion KRW | 11.18% |
| 2022 | 2375.81 Billion KRW | 134.56% |
| 2021 | 1012.87 Billion KRW | 56.8% |
| 2020 | 645.96 Billion KRW | 42.76% |
| 2019 | 452.46 Billion KRW | 49.65% |
| 2018 | 302.36 Billion KRW | 43.99% |
| 2017 | 209.98 Billion KRW | 27.87% |
| 2016 | 164.21 Billion KRW | 37.79% |
| 2015 | 119.17 Billion KRW | 60.18% |
| 2014 | 74.4 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 2761.26 Billion KRW | 3.76% |
| 2024 Q1 | 2661.18 Billion KRW | 0.75% |
| 2023 Q2 | 2529.88 Billion KRW | 3.77% |
| 2023 Q3 | 2551.22 Billion KRW | 0.84% |
| 2023 Q4 | 2641.36 Billion KRW | 3.53% |
| 2023 FY | 2641.36 Billion KRW | 11.18% |
| 2023 Q1 | 2437.97 Billion KRW | 2.62% |
| 2022 FY | 2375.81 Billion KRW | 134.56% |
| 2022 Q4 | 2375.81 Billion KRW | -0.57% |
| 2022 Q3 | 2389.42 Billion KRW | 3.6% |
| 2022 Q1 | 1012.84 Billion KRW | -0.0% |
| 2022 Q2 | 2306.42 Billion KRW | 127.72% |
| 2021 Q2 | 879.62 Billion KRW | 11.59% |
| 2021 Q4 | 1012.87 Billion KRW | 5.55% |
| 2021 Q1 | 788.27 Billion KRW | 22.03% |
| 2021 FY | 1012.87 Billion KRW | 56.8% |
| 2021 Q3 | 959.64 Billion KRW | 9.1% |
| 2020 Q1 | 505.88 Billion KRW | 11.81% |
| 2020 Q2 | 495.67 Billion KRW | -2.02% |
| 2020 Q3 | 555.76 Billion KRW | 12.12% |
| 2020 FY | 645.96 Billion KRW | 42.76% |
| 2020 Q4 | 645.96 Billion KRW | 16.23% |
| 2019 Q4 | 452.46 Billion KRW | 1.53% |
| 2019 FY | 452.46 Billion KRW | 49.65% |
| 2019 Q3 | 445.66 Billion KRW | 7.27% |
| 2019 Q2 | 415.47 Billion KRW | 29.61% |
| 2019 Q1 | 320.55 Billion KRW | 6.02% |
| 2018 FY | 302.36 Billion KRW | 43.99% |
| 2018 Q1 | 223.53 Billion KRW | 6.45% |
| 2018 Q2 | 231.58 Billion KRW | 3.6% |
| 2018 Q3 | 284.2 Billion KRW | 22.72% |
| 2018 Q4 | 302.36 Billion KRW | 6.39% |
| 2017 Q2 | 194.03 Billion KRW | 25.66% |
| 2017 Q1 | 154.4 Billion KRW | -5.97% |
| 2017 FY | 209.98 Billion KRW | 27.87% |
| 2017 Q3 | 194.62 Billion KRW | 0.31% |
| 2017 Q4 | 209.98 Billion KRW | 7.89% |
| 2016 FY | 164.21 Billion KRW | 37.79% |
| 2016 Q4 | 164.21 Billion KRW | 0.0% |
| 2015 FY | 119.17 Billion KRW | 60.18% |
| 2014 FY | 74.4 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.65 Billion KRW | -72178.933% |
| Green Cross Holdings Corporation | 579.72 Billion KRW | -355.622% |
| Green Cross Holdings Corporation | 516.24 Billion KRW | -411.65% |
| Pharmicell Co., Ltd. | 20.87 Billion KRW | -12554.85% |
| Green Cross Corporation | 516.24 Billion KRW | -411.65% |
| GeneOne Life Science, Inc. | 14.89 Billion KRW | -17630.94% |
| Celltrion, Inc. | 3041.45 Billion KRW | 13.154% |
| SK bioscience Co.,Ltd. | 80.64 Billion KRW | -3175.126% |
| SK Biopharmaceuticals Co., Ltd. | 102.52 Billion KRW | -2476.304% |
| Prestige BioPharma Limited | 18.1 Billion KRW | -14490.778% |